Media reports over delays to the completion of Aurobindo’s deal to acquire Sandoz’ US dermatology and oral-solids businesses contain inaccuracies and mischaracterize the current status of the regulatory approval process, according to the Indian company.
Aurobindo Hits Back Over Sandoz Delay Rumors
Media Reports On FTC Discussions Are ‘Factually Inaccurate’
Aurobindo has hit back over rumors that completion of its pending transaction to acquire Sandoz’ US dermatology and oral-solids businesses has been delayed until next year over FTC information requests.
